Clinical Trials Logo

Idiopathic Juvenile Arthritis clinical trials

View clinical trials related to Idiopathic Juvenile Arthritis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05045001 Recruiting - Clinical trials for Rheumatoid Arthritis

Pharmacogenetic Studies on Anti-IL-6 Receptor Monoclonal Antibodies on the Treatment of Rheumatic Diseases

Start date: June 2, 2021
Phase:
Study type: Observational

Tocilizumab and Sarilumab are first-line biological disease-modifying anti-rheumatic drug (bDMARD) which inhibits Interleukin 6 (IL-6) pathway through blockade of its receptor on the treatment of Rheumatoid Arthritis and other rheumatic diseases as Giant Cell Arteritis, Still's disease and Idiopathic Juvenile Arthritis. At present, there is a lack of evidence to recommend the treatment of one bDMARD over another. Seeking for genetic biomarkers to predict response to treatment could be key towards a personalized treatment strategy in rheumatology. The investigators aime to evaluate whether functional single nucleotide polymorphisms (SNPs) in the IL6R gene could predict response and/or toxicity in patients with rheumatic diseases treated with anti-IL-6 receptor drugs.

NCT ID: NCT02343770 Recruiting - Clinical trials for Idiopathic Juvenile Arthritis

Biomarkers in Idiopathic Juvenile Arthritis

Start date: June 2015
Phase: N/A
Study type: Interventional

Juvenile idiopathic arthritis (JIA) is the most common form of arthritis in children. The etiology is unknown. Several types of arthritis fall under the JIA heading. Oligoarticular JIA with antinuclear antibodies affects about half of all children. There 's no specific markers. Our purpose is to identify new markers in this pathology. The ProtoArray®Human Protein Microarray allows rapid and efficient detection of protein interaction using a suitable protein or small molecule probe. The investigators hope so detect novel potential autoantigen biomarkers specific in JIA.